Equities Analysts Set Expectations for NRIX FY2025 Earnings

Nurix Therapeutics, Inc. (NASDAQ:NRIX) – Analysts at Leerink Partnrs upped their FY2025 earnings per share estimates for shares of Nurix Therapeutics in a research report issued on Wednesday, October 22nd. Leerink Partnrs analyst F. Khurshid now forecasts that the company will earn ($3.05) per share for the year, up from their prior forecast of ($3.33). The consensus estimate for Nurix Therapeutics’ current full-year earnings is ($2.99) per share. Leerink Partnrs also issued estimates for Nurix Therapeutics’ Q4 2025 earnings at ($0.81) EPS, Q1 2026 earnings at ($0.76) EPS, Q2 2026 earnings at ($0.78) EPS, Q3 2026 earnings at ($0.80) EPS, Q4 2026 earnings at ($0.87) EPS and FY2026 earnings at ($3.20) EPS.

NRIX has been the topic of a number of other reports. Oppenheimer decreased their price objective on Nurix Therapeutics from $30.00 to $28.00 and set an “outperform” rating on the stock in a research report on Friday, October 10th. UBS Group decreased their price objective on Nurix Therapeutics from $30.00 to $26.00 and set a “buy” rating on the stock in a research report on Thursday, July 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nurix Therapeutics in a research report on Wednesday, October 8th. Mizuho started coverage on Nurix Therapeutics in a research report on Tuesday, October 21st. They issued an “outperform” rating and a $24.00 price objective on the stock. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $27.00 price objective on shares of Nurix Therapeutics in a research report on Monday, October 20th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Nurix Therapeutics has an average rating of “Moderate Buy” and an average target price of $27.07.

Nurix Therapeutics Price Performance

NASDAQ NRIX opened at $11.98 on Monday. The firm has a market cap of $921.02 million, a PE ratio of -4.03 and a beta of 2.33. Nurix Therapeutics has a one year low of $8.18 and a one year high of $29.56. The stock’s 50 day simple moving average is $9.52 and its 200 day simple moving average is $10.56.

Nurix Therapeutics (NASDAQ:NRIX) last released its quarterly earnings results on Thursday, October 9th. The company reported ($1.03) EPS for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.19). The business had revenue of $7.89 million for the quarter, compared to the consensus estimate of $16.06 million. Nurix Therapeutics had a negative return on equity of 53.57% and a negative net margin of 292.50%.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Sumitomo Mitsui Trust Group Inc. boosted its position in shares of Nurix Therapeutics by 11.9% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,557,479 shares of the company’s stock worth $14,391,000 after purchasing an additional 165,841 shares during the last quarter. SG Americas Securities LLC acquired a new stake in Nurix Therapeutics during the 3rd quarter worth $203,000. Nikko Asset Management Americas Inc. raised its stake in Nurix Therapeutics by 83.8% during the 2nd quarter. Nikko Asset Management Americas Inc. now owns 1,389,274 shares of the company’s stock worth $15,796,000 after buying an additional 633,304 shares during the period. Tower Research Capital LLC TRC raised its stake in Nurix Therapeutics by 118.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,413 shares of the company’s stock worth $73,000 after buying an additional 3,475 shares during the period. Finally, Vestal Point Capital LP raised its stake in Nurix Therapeutics by 77.7% during the 2nd quarter. Vestal Point Capital LP now owns 2,000,000 shares of the company’s stock worth $22,780,000 after buying an additional 874,448 shares during the period.

Insider Buying and Selling at Nurix Therapeutics

In other news, CFO Houte Hans Van sold 5,402 shares of the firm’s stock in a transaction on Friday, August 1st. The stock was sold at an average price of $11.03, for a total value of $59,584.06. Following the transaction, the chief financial officer directly owned 35,512 shares in the company, valued at $391,697.36. This trade represents a 13.20% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Gwenn Hansen sold 4,308 shares of the firm’s stock in a transaction on Wednesday, July 30th. The stock was sold at an average price of $12.01, for a total value of $51,739.08. Following the completion of the transaction, the insider owned 69,023 shares in the company, valued at $828,966.23. This represents a 5.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 14,014 shares of company stock worth $163,014 over the last 90 days. 7.40% of the stock is owned by corporate insiders.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.